Toggle menu


Start date:
March 2021
End date:
March 2022
Co-ordinated by:
Main trial site:
Royal Infirmary of Edinburgh

This trial is an open label two-arm randomised trial focused on identifying the best treatment for community acquired sepsis patients. We will be investigating the feasibility of delivering early intravenous fluid resuscitation by comparing 5% human albumin solution (HAS) to balanced crystalloid. Currently, balanced crystalloids are used as routine care and the first line therapy in the international sepsis guidelines, whereas HAS is the second line fluid therapy in septic shock. Although, studies are showing that HAS may have further potential benefits to patients with sepsis.

The study aims to recruit 300 patients who meet the following inclusion criteria:

  1. Clinically suspected or proven infection resulting in principal reason for acute illness;
  2. NEWS/NEWS2 score ≥5;
  3. Hospital presentation within last 12hrs;
  4. 4.Clinician decision has been made that immediate (within 1 hour of assessment) intravenous fluid resuscitation is needed; and;
  5. Ability to obtain informed consent.

Patients will be recruited in the Emergency Department and Medical and Surgical Assessment Units across UK NHS hospitals. The treatment will be administered within the first 6 hours of randomisation. Following this, patients will be reviewed for safety reasons and asked to complete a questionnaire in order to evaluate thier quality of life.

Research Team

Julia Grahamslaw

Lead Research Nurse

Miranda Odam

Research Nurse Manager

Rachel O'Brien

Lead Research Nurse

Polly Black

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Fiona McCurrach

Senior Research Nurse

Alison Grant

Senior Research Nurse

Alison Williams

Senior Research Nurse

Lisa Donald

Research Nurse

Emma Moatt

Research Project Manager

Nicholas Fethers

Research Administrator

Rebecca Trainer

Administrative Assistant

More EMERGE Trials

DASH Trial

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.